Fast forward to today, and to-date Bayer has paid more than $10 billion to plaintiffs in litigation claiming Roundup as the cause of their cancer. And per CEO Bill Anderson in a Wall Street ...

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter results missed Wall Street ... March 14, 2025 Bayer wins Brazil injunction in soy patent row with farmers ...

In March, Bayer AG’s cancer drug, Nexavar (sorafenib), was stripped of its patent on the grounds that its expensive cost put it out of the reach of ordinary people. The hearing is expected to ...